Fuller & Thaler Asset Management Inc. Has $36.63 Million Holdings in Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• Fuller & Thaler Asset Management Inc. increased its stake in Amphastar Pharmaceuticals by 11.5% during the first quarter, holding approximately $36.6 million worth of shares.
• Amphastar Pharmaceuticals has received mixed ratings from analysts, with Needham raising it to a "buy" and JPMorgan cutting its price target significantly from $45 to $30.
• The company currently has a market cap of $1.41 billion, with its stock showing a 1-year range from a low of $20.39 to a high of $53.96.

Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 11.5% in the first quarter, according to its most recent filing with the SEC. The firm owned 1,263,598 shares of the company's stock after acquiring an additional 130,672 shares during the period. Fuller & Thaler Asset Management Inc. owned 2.66% of Amphastar Pharmaceuticals worth $36,632,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in the stock. TD Asset Management Inc boosted its position in shares of Amphastar Pharmaceuticals by 20.2% in the 1st quarter. TD Asset Management Inc now owns 2,212,142 shares of the company's stock worth $64,130,000 after purchasing an additional 371,856 shares during the last quarter. Boston Trust Walden Corp boosted its holdings in Amphastar Pharmaceuticals by 24.2% during the first quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company's stock worth $35,241,000 after buying an additional 236,704 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Amphastar Pharmaceuticals by 9.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock worth $44,503,000 after buying an additional 105,288 shares during the period. Northern Trust Corp increased its stake in shares of Amphastar Pharmaceuticals by 5.1% in the 4th quarter. Northern Trust Corp now owns 613,170 shares of the company's stock valued at $22,767,000 after acquiring an additional 29,808 shares during the last quarter. Finally, Royce & Associates LP raised its position in shares of Amphastar Pharmaceuticals by 2,684.3% in the 1st quarter. Royce & Associates LP now owns 247,858 shares of the company's stock valued at $7,185,000 after acquiring an additional 238,956 shares during the period. Institutional investors and hedge funds own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Up 2.8%

AMPH traded up $0.84 during trading on Friday, hitting $30.50. The company had a trading volume of 494,895 shares, compared to its average volume of 642,582. The company has a market capitalization of $1.42 billion, a PE ratio of 11.42 and a beta of 0.76. The company has a quick ratio of 2.21, a current ratio of 3.29 and a debt-to-equity ratio of 0.80. Amphastar Pharmaceuticals, Inc. has a one year low of $20.39 and a one year high of $53.96. The firm's 50-day moving average price is $24.10 and its 200 day moving average price is $25.82.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Wells Fargo & Company dropped their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a report on Friday, August 8th. Finally, Needham & Company LLC upgraded Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price target for the company in a report on Tuesday, August 12th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $31.50.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.